Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.
Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.
The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.
Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.
Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.
Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.
Investigators found no statistically significant difference in survival between radical prostatectomy alone and external beam radiotherapy plus brachytherapy with or without ADT after adjusting for imbalances in prostate cancer prognostic factors.
Erik P. Castle, MD, discusses the importance of risk stratifying low- and intermediate-risk localized prostate cancers.
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.